JP2011527345A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011527345A5 JP2011527345A5 JP2011517507A JP2011517507A JP2011527345A5 JP 2011527345 A5 JP2011527345 A5 JP 2011527345A5 JP 2011517507 A JP2011517507 A JP 2011517507A JP 2011517507 A JP2011517507 A JP 2011517507A JP 2011527345 A5 JP2011527345 A5 JP 2011527345A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- item
- aryl
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 75
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 35
- 125000003118 aryl group Chemical group 0.000 claims description 34
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 27
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 18
- 150000004820 halides Chemical class 0.000 claims description 18
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 125000003342 alkenyl group Chemical group 0.000 claims description 12
- 150000007942 carboxylates Chemical group 0.000 claims description 11
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 8
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 7
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims description 6
- 125000003860 C1-C20 alkoxy group Chemical group 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000003107 substituted aryl group Chemical group 0.000 claims description 5
- 101710091951 Glycerol-3-phosphate acyltransferase Proteins 0.000 claims description 2
- 229910019142 PO4 Chemical group 0.000 claims description 2
- 150000001735 carboxylic acids Chemical group 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 2
- 235000021317 phosphate Nutrition 0.000 claims description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 2
- 150000003013 phosphoric acid derivatives Chemical group 0.000 claims description 2
- 230000004580 weight loss Effects 0.000 claims description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 150000001925 cycloalkenes Chemical class 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 238000000034 method Methods 0.000 description 9
- 125000005843 halogen group Chemical group 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- -1 phenyl ring compound Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12957808P | 2008-07-07 | 2008-07-07 | |
| US61/129,578 | 2008-07-07 | ||
| PCT/US2009/049744 WO2010005922A1 (en) | 2008-07-07 | 2009-07-07 | Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011527345A JP2011527345A (ja) | 2011-10-27 |
| JP2011527345A5 true JP2011527345A5 (enExample) | 2012-08-16 |
Family
ID=41507395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011517507A Pending JP2011527345A (ja) | 2008-07-07 | 2009-07-07 | 新規な化合物、この化合物を含む医薬組成物、この化合物の使用方法、およびこの化合物の調製方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120083471A1 (enExample) |
| EP (1) | EP2303013A1 (enExample) |
| JP (1) | JP2011527345A (enExample) |
| CN (1) | CN102395270B (enExample) |
| CA (1) | CA2729767A1 (enExample) |
| MX (1) | MX2011000051A (enExample) |
| WO (1) | WO2010005922A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| EP2598481B1 (en) | 2010-07-26 | 2016-08-31 | Bristol-Myers Squibb Company | Sulfonamide compounds useful as cyp17 inhibitors |
| CA2822039C (en) * | 2010-12-16 | 2019-05-28 | Allergan, Inc. | Sulfur derivatives as chemokine receptor modulators |
| TW201300358A (zh) * | 2011-03-14 | 2013-01-01 | 大正製藥股份有限公司 | 含氮縮合雜環化合物 |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013155528A2 (en) * | 2012-04-13 | 2013-10-17 | Fasgen, Inc. | Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels |
| KR102301867B1 (ko) | 2013-12-18 | 2021-09-15 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 조절제 |
| US9701627B2 (en) * | 2014-06-16 | 2017-07-11 | University Of Maryland, Baltimore | LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders |
| WO2016172218A1 (en) * | 2015-04-20 | 2016-10-27 | The Regents Of The University Of Michigan | Small molecule inhibitors of mcl-1 and uses thereof |
| ES2834490T3 (es) | 2015-06-15 | 2021-06-17 | Glaxosmithkline Ip Dev Ltd | Reguladores de NRF2 |
| US10604509B2 (en) | 2015-06-15 | 2020-03-31 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
| US10364256B2 (en) | 2015-10-06 | 2019-07-30 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as NRF2 regulators |
| WO2019165232A1 (en) * | 2018-02-23 | 2019-08-29 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibitors of phospholipid synthesis and methods of use |
| WO2021035031A1 (en) * | 2019-08-21 | 2021-02-25 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibitors of phospholipid synthesis and methods of use |
| AR127055A1 (es) | 2021-09-14 | 2023-12-13 | Lilly Co Eli | Sales agonistas de sstr4 |
| WO2025140544A1 (zh) * | 2023-12-28 | 2025-07-03 | 南京瑞初医药有限公司 | Gsdmd抑制剂及其用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2531367A (en) * | 1947-07-15 | 1950-11-21 | Sharp & Dohme Inc | N-(substituted sulfonyl)-aminobenzoic acids |
| DE2611705A1 (de) * | 1976-03-18 | 1977-09-22 | Josef Dipl Chem Dr Rer N Klosa | N-5-(nitrofurfuryliden-)-1-amino- hydantoin enthaltende kristalloesungsmittel |
| DE3000377A1 (de) * | 1980-01-07 | 1981-07-09 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
| FR2509305B1 (fr) * | 1981-07-08 | 1986-04-18 | Sanofi Sa | Benzamides, procede pour leur preparation et compositions pharmaceutiques les renfermant |
| AU567140B2 (en) * | 1984-01-06 | 1987-11-12 | Shionogi & Co., Ltd. | Sulphonamido-benzamide derivatives |
| DE4003054A1 (de) * | 1990-02-02 | 1991-08-08 | Hoechst Ag | Verwendung von benzylphosphonsaeurederivaten zur behandlung von durch viren verursachte krankheiten |
| DE69023336T2 (de) * | 1990-08-22 | 1996-05-30 | Agfa Gevaert Nv | Partikeltonermaterial. |
| JP3577336B2 (ja) * | 1994-04-26 | 2004-10-13 | 三井化学株式会社 | 感熱記録材料 |
| US5981575A (en) * | 1996-11-15 | 1999-11-09 | Johns Hopkins University, The | Inhibition of fatty acid synthase as a means to reduce adipocyte mass |
| US20030124187A1 (en) * | 1997-02-14 | 2003-07-03 | Smithkline Beecham Laboratoires Pharmaceutiques, | Pharmaceutical formulations comprising amoxycillin and clavulanate |
| JP2000006528A (ja) * | 1998-06-25 | 2000-01-11 | Fuji Photo Film Co Ltd | 感熱記録材料 |
| US6048680A (en) * | 1998-12-09 | 2000-04-11 | Eastman Kodak Company | Photographic element containing pyrazoloazole coupler and a specific anti-fading combination |
| JP2000302793A (ja) * | 1999-02-18 | 2000-10-31 | Ono Pharmaceut Co Ltd | ホスホン酸誘導体 |
| DE10121003A1 (de) * | 2001-04-28 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| AU2002348276A1 (en) * | 2001-11-16 | 2003-06-10 | Bristol-Myers Squibb Company | Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein |
| US7119120B2 (en) * | 2001-12-26 | 2006-10-10 | Genzyme Corporation | Phosphate transport inhibitors |
| DK1471890T3 (da) * | 2002-02-07 | 2007-01-08 | Pharmacia Corp | Farmaceutisk doseringsform til mukös afgivelse |
| AU2003258491A1 (en) * | 2002-09-05 | 2004-03-29 | Neurosearch A/S | Amide derivatives and their use as chloride channel blockers |
| US7229966B2 (en) * | 2002-12-17 | 2007-06-12 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity |
| AU2004210162A1 (en) * | 2003-01-29 | 2004-08-19 | Panacos Pharmaceuticals, Inc. | Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein |
| DE602006003661D1 (de) * | 2005-06-06 | 2008-12-24 | Lilly Co Eli | Ampa-rezeptoren-verstärker |
| GB0526252D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| WO2008010934A2 (en) * | 2006-07-14 | 2008-01-24 | Chemocentryx, Inc. | Triazolyl phenyl benzenesulfonamides |
| PT2056815E (pt) * | 2006-08-16 | 2013-04-03 | Amderma Pharmaceuticals Llc | Utilização de derivados de 2,5-dihidroxibenzeno para tratar dermatite |
-
2009
- 2009-07-07 WO PCT/US2009/049744 patent/WO2010005922A1/en not_active Ceased
- 2009-07-07 CA CA2729767A patent/CA2729767A1/en not_active Abandoned
- 2009-07-07 EP EP09795032A patent/EP2303013A1/en not_active Withdrawn
- 2009-07-07 MX MX2011000051A patent/MX2011000051A/es unknown
- 2009-07-07 JP JP2011517507A patent/JP2011527345A/ja active Pending
- 2009-07-07 CN CN200980135092.1A patent/CN102395270B/zh not_active Expired - Fee Related
-
2011
- 2011-10-14 US US13/273,740 patent/US20120083471A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011527345A5 (enExample) | ||
| AU2014219283C1 (en) | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | |
| JP2013532652A5 (enExample) | ||
| ES2624291T3 (es) | Inhibidores cíclicos del enlace éter de DGAT1 | |
| JP2009530398A5 (enExample) | ||
| JP2010077141A5 (enExample) | ||
| JP2009504764A5 (enExample) | ||
| SI2303270T1 (en) | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceutical products | |
| JP2013510825A5 (enExample) | ||
| JPWO2020123827A5 (enExample) | ||
| JP6261011B2 (ja) | 眼疾患処置薬 | |
| JP2016520618A5 (enExample) | ||
| JP2013508279A5 (enExample) | ||
| JP2016518437A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| JP2009543795A5 (enExample) | ||
| JP2019500387A5 (enExample) | ||
| JP2016531871A5 (enExample) | ||
| JP2014505107A5 (enExample) | ||
| JP2014530837A5 (enExample) | ||
| JP2018502101A5 (enExample) | ||
| JP2010155827A5 (enExample) | ||
| JP2015521156A5 (enExample) | ||
| RU2013108348A (ru) | Конденсированные гетероарилы и их применение | |
| JP2014505017A5 (enExample) |